RecruitingNCT06497777

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.


Sponsor

National Taiwan University Hospital

Enrollment

30 participants

Start Date

Jul 6, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.


Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new blood test using tiny DNA machines (nanomachines) that can detect specific microRNA markers to help diagnose pancreatic cancer earlier and more accurately. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), confirmed by pathology (tissue testing) - You have not yet received any cancer treatment (surgery, chemotherapy, or radiation) - You are 20 years old or older **You may NOT be eligible if...** - You are under 20 years old or unable to provide informed consent - You have another active cancer in addition to pancreatic cancer - You have completed or are currently undergoing cancer treatment for pancreatic cancer - Your expected survival is less than 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICMicroRNA (mir-642b-3p)

A circulating microRNA in the blood of pancreatic cancer patients.


Locations(1)

National Taiwan University Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06497777


Related Trials